Eli Lilly is absolutely crushing it! Their latest financial report shows they've not only surpassed expectations for the fourth quarter but are also projecting an incredibly strong future, largely thanks to the runaway success of their groundbreaking drugs, Zepbound and Mounjaro. It's a story of immense growth in a highly competitive market.
Let's dive into what makes this news so significant. Eli Lilly, a titan in the pharmaceutical world, announced results that left Wall Street cheering. They've projected their 2026 revenue to soar between $80 billion and $83 billion, a figure that comfortably outstrips the $77.62 billion analysts had anticipated. On the earnings front, they're looking at adjusted earnings per share between $33.50 and $35, again beating the $33.23 estimate.
But here's where it gets interesting: This incredible performance comes at a time when a major rival, Novo Nordisk, has issued a more cautious outlook, predicting declining sales and profits for the current year. This is largely due to falling prices in the U.S. and the expiry of patent protections for their key obesity and diabetes drugs in crucial international markets like China, Brazil, and Canada.
Eli Lilly, however, seems determined to maintain its leading position in the rapidly expanding market for GLP-1 drugs – the class of medications that includes their popular treatments. While Novo Nordisk is celebrating the U.S. launch of its new obesity pill, Wegovy, Lilly is also working on expanding its own portfolio. They're hoping for approval of their oral weight-loss drug, orforglipron, later this year, aiming to capture an even larger share of this lucrative market.
Let's look at the numbers for the fourth quarter:
- Adjusted Earnings Per Share: A remarkable $7.54, significantly higher than the $6.67 expected.
- Revenue: A massive $19.29 billion, soaring past the $17.96 billion forecast.
This represents a staggering 43% increase in revenue compared to the same period last year. The U.S. market was a huge driver, with revenue climbing to $12.9 billion. Eli Lilly attributes this to a 50% surge in the volume of prescriptions for Mounjaro and Zepbound. While they did note a slight decrease in the realized prices of these drugs, the sheer increase in demand more than compensated.
Financially, the company reported a net income of $6.64 billion, or $7.39 per share, a substantial leap from the $4.41 billion, or $4.88 per share, recorded a year prior. After accounting for certain one-time items, the adjusted earnings per share stood at $7.54.
And this is the part most people miss: In November, both Novo Nordisk and Eli Lilly announced significant agreements with the Trump administration to reduce the prices of their top-selling obesity and diabetes drugs. While these deals are expected to boost prescription numbers in the long run, they could initially impact total sales. Under these agreements, Lilly and Novo will lower prices for Medicare and Medicaid beneficiaries starting in 2026 and offer discounts through a new direct-to-consumer platform. In exchange, they've secured a three-year exemption from tariffs.
Eli Lilly's CEO, Dave Ricks, acknowledged in a recent interview that there would be a "step down in pricing" early this year due to this agreement. However, he expressed confidence that the volume growth of their drugs would accelerate in the latter half of the year, suggesting a strategic long-term vision.
This all paints a picture of a company not just succeeding, but actively shaping the future of a critical therapeutic area. What are your thoughts on these groundbreaking GLP-1 drugs and their impact on the market? Do you believe the pricing agreements will ultimately benefit patients and the companies in the long run? Let's discuss in the comments!
